These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 1718067)

  • 1. OKT3E, an anti-CD3 antibody that does not elicit side effects or antiidiotype responses in chimpanzees.
    Rao PE; Olini G; Kille J; Muchmore E; Talle MA; Brake G; Rudnick SA
    Transplantation; 1991 Oct; 52(4):691-7. PubMed ID: 1718067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-CD3 monoclonal antibody therapy. An approach toward optimization by in vitro analysis of new anti-CD3 antibodies.
    Woodle ES; Thistlethwaite JR; Jolliffe LK; Fucello AJ; Stuart FP; Bluestone JA
    Transplantation; 1991 Aug; 52(2):361-8. PubMed ID: 1714644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OKT3 induction via idiotypic networks of mirror-image immunosuppressive antiimmunoglobulins in renal transplant recipients.
    Carreno M; Yang WC; Esquenazi V; Fuller L; Burke G; Milgrom M; Roth D; Ranjan D; Miller J
    Transplantation; 1990 Feb; 49(2):408-15. PubMed ID: 1689519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of anti-CD3 antibodies that do not modulate antigen but induce mitogenesis and block the mixed lymphocyte reaction.
    Rao PE; Newman W; Meyer E; Fahmy B; Talle MA; Fanning VA
    Hum Immunol; 1992 Apr; 33(4):275-83. PubMed ID: 1386354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Murine monoclonal IgG antibodies: differences in their IgG isotypes can affect the antibody effector activity when using human cells.
    Lobo PI; Patel HC
    Immunol Cell Biol; 1997 Jun; 75(3):267-74. PubMed ID: 9243292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful retreatment of allograft rejection with OKT3.
    First MR; Schroeder TJ; Hurtubise PE; Mansour ME; Penn I; Munda R; Balistreri WF; Alexander JW; Melvin DB; Fidler JP
    Transplantation; 1989 Jan; 47(1):88-91. PubMed ID: 2521410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regional and systemic distribution of anti-tumor x anti-CD3 heteroaggregate antibodies and cultured human peripheral blood lymphocytes in a human colon cancer xenograft.
    Nelson H; Ramsey PS; Kerr LA; McKean DJ; Donohue JH
    J Immunol; 1990 Nov; 145(10):3507-15. PubMed ID: 1700013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-species reactivity of the anti-idiotype anti-OKT3 cascade between mice and humans.
    Carreno M; Fuller L; Zucker K; Yang WC; Burke G; Nery J; Gomez C; Esquenazi V; Miller J
    Hum Immunol; 1992 Apr; 33(4):249-58. PubMed ID: 1386353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunologic monitoring with Orthoclone OKT3 therapy.
    Schroeder TJ; First MR; Hurtubise PE; Marmer DJ; Martin DM; Mansour ME; Melvin DB
    J Heart Transplant; 1989; 8(5):371-80. PubMed ID: 2529358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal antibodies to common epitopes of the human alpha/beta T-cell receptor preferentially activate CD45RA+ T-cells.
    Schwinzer R; Schlitt HJ; Wonigeit K
    Cell Immunol; 1992 Mar; 140(1):31-41. PubMed ID: 1531453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T cells from patients successfully treated with OKT3 do not react with the T-cell receptor antibody.
    Gebel HM; Lebeck LK; Jensik SC; Webster K; Bray RA
    Hum Immunol; 1989 Oct; 26(2):123-9. PubMed ID: 2479623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of antibody isotype in IFN-gamma and IL-2 production during anti-CD3-induced T cell proliferation.
    Frenken LA; Koene RA; Tax WJ
    Transplantation; 1991 Apr; 51(4):881-7. PubMed ID: 1826571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal antibodies to murine CD3 epsilon define distinct epitopes, one of which may interact with CD4 during T cell activation.
    Portoles P; Rojo J; Golby A; Bonneville M; Gromkowski S; Greenbaum L; Janeway CA; Murphy DB; Bottomly K
    J Immunol; 1989 Jun; 142(12):4169-75. PubMed ID: 2470817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The mechanism of anti-CD3 monoclonal antibodies. Mediation of cytolysis by inter-T cell bridging.
    Wong JT; Eylath AA; Ghobrial I; Colvin RB
    Transplantation; 1990 Oct; 50(4):683-9. PubMed ID: 2145670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The improved lytic function and in vivo efficacy of monovalent monoclonal CD3 antibodies.
    Clark M; Bindon C; Dyer M; Friend P; Hale G; Cobbold S; Calne R; Waldmann H
    Eur J Immunol; 1989 Feb; 19(2):381-8. PubMed ID: 2522881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of OKT3 in clinical transplantation.
    Norman DJ; Leone MR
    Pediatr Nephrol; 1991 Jan; 5(1):130-6. PubMed ID: 1827342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Nephrotoxicity of anti-CD3 monoclonal antibodies].
    Alegre ML; Depierreux M; Florquin S; Abramowicz D; De Pauw L; Kinnaert P; Vereerstraeten P; Goldman M
    Nephrologie; 1991; 12(1):42-5. PubMed ID: 1827878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variation in patient response associated with different preparations of murine monoclonal antibody therapy.
    Delmonico FL; Fuller TC; Russell PS; Colvin RB; Cosimi AB
    Transplantation; 1989 Jan; 47(1):92-5. PubMed ID: 2521411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of human T cells in vivo following treatment of transplant recipients with OKT3.
    Ellenhorn JD; Woodle ES; Ghobreal I; Thistlethwaite JR; Bluestone JA
    Transplantation; 1990 Oct; 50(4):608-12. PubMed ID: 2145669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute toxicity of anti-CD3 monoclonal antibody in mice: a model for OKT3 first dose reactions.
    Alegre M; Depierreux M; Florquin S; Najdovski T; Vandenabeele P; Abramowicz D; Leo O; Deschodt-Lanckman M; Goldman M
    Transplant Proc; 1990 Aug; 22(4):1920-1. PubMed ID: 2143864
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.